VaxInnate Licenses Recombinant H1N1 Pandemic Swine Flu Vaccine to Biological E.; Vaccine Could Become Available for Use in India This Year

Former Wyeth Executive Joins VaxInnate as Chief Operating Officer 
Dr. Hofstaetter is also a member of the VaxInnate Board of Directors.

FierceBiotech Names VaxInnate as One of the “Fierce 15" Biotech Companies of 2009 
VaxInnate is “Fierce,” on Leading Edge of Biotech

VaxInnate Reports Positive Results from Preclinical Testing

of Swine Flu Vaccine Developed Using Novel Technology 
 

VaxInnate Takes Aim at Swine Flu 
What is VaxInnate doing to address the Swine Flu (H1N1 influenza A) outbreak?

VaxInnate Corporation Closes $30 Million Round of Financing;Wellcome Trust Leads Round 
Emerging swine flu among targets for development of novel vaccines

VaxInnate's Seasonal Flu Vaccine Candidate Shown Safe and Immunogenic in Phase I Study 
Novel technology could transform flu vaccine product 

VaxInnate Welcomes David J. Williams to its Board of Directors
Retired Chairman/CEO of Sanofi Pasteur brings 30 years of vaccine experience and leadership.

VaxInnate announces 'universal' flu vaccine passed early test
"VaxInnate's M2e universal flu vaccine candidate has passed a critical initial test," David Taylor, MD, the company's chief medical officer, said in the news release.

VaxInnate on NJN - Interview with Dr. Bob Becker
VaxInnate is marking some milestones in the development in new vaccine technology which might be a new solution to flu shots.

VaxInnate on U.S.1 - Taking Chickens Out of the Vaccine
VaxInnate’s flu vaccine is now in the human testing phase, and could be ready for market within several years.

VaxInnate’s Universal Flu Vaccine Candidate Shown Safe and Immunogenic in Phase I Clinical Study
Study validates proprietary technology that could transform flu vaccine production

3M and VaxInnate Collaborate to Develop Flu Vaccine Patch
3M Drug Delivery Systems has entered into an agreement with VaxInnate Corporation to develop a flu vaccine patch for use against a pandemic flu outbreak.

VaxInnate To Present Positive Results from Clinical Trial of Universal Flu Vaccine Candidate at ICAAC/IDSA Meeting
VaxInnate Corporation, a biotechnology company pioneering breakthrough technology to develop novel seasonal and pandemic influenza vaccines

VaxInnate's Second Flu Vaccine Candidate Enters Clinical Deployment; Results Expected in Early 2009
Study Tests Novel Technology with Potential to Transform Production of Flu Vaccines

VaxInnate's M2e Universal Influenza Vaccine Candidate Demonstrates Safety and Immunogenicity in Phase I Clinical Study
Novel Technology Could Transform Production of Flu Vaccine With Enhanced Potency, Manufacturing Capacity and Cost-Effectiveness

VaxInnate Initiates Phase I Clinical Study of M2e Universal Influenza Vaccine
Company's First Clinical Trial Studies Vaccine Based on New Vaccine Technology

VaxInnate Awarded NIH Funding for Collaborative Dengue Fever Vaccine Development
Award based on TLR technology platform’s application in developing vaccines for Flavivirus and other infectious diseases

David Taylor, MD, Joins VaxInnate as Chief Medical Officer
Dr. Taylor's Extensive Experience in Infectious Disease and Vaccine Research Will Support Advancement of Avian and Seasonal Influenza, Malaria Vaccines